Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on RSS
Abstract

Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate.

Michael Seitz, Marianne Zwicker and Peter M Villiger
The Journal of Rheumatology January 2003, 30 (1) 28-35;
Michael Seitz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marianne Zwicker
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter M Villiger
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

OBJECTIVE: To determine the role of putative target cytokines for methotrexate (MTX) treatment in patients with rheumatoid arthritis (RA) as predictors for treatment outcome. METHODS: Fifty consecutive patients with RA were characterized according to demographic and disease associated features and followed prospectively before and after 6 months of treatment with MTX. Before starting MTX treatment, serum was obtained from each patient and peripheral blood mononuclear cells (PBMC) were isolated. PBMC were cultured 2 days under resting conditions, and interleukin 1 receptor antagonist (IL-1ra), IL-1beta, soluble tumor necrosis factor receptor p55+75 (sTNFR p55+p75), and TNF-a release into cell culture supernatants and corresponding serum cytokine levels were determined by specific ELISA. Constitutive production and circulating levels of cytokines and cytokine inhibitors were correlated to the clinical response after 6 months of MTX treatment, and patients were categorized into 4 different groups according to the American College of Rheumatology (ACR) response criteria (ACR < 20, 20-50, 50-70, > 70% improvement from baseline). RESULTS: Good (ACR 50-70) or excellent (ACR > 70) responses to MTX treatment were seen in groups of patients with a higher proportion of males (25 and 43%) associated with a significantly lower ratio of IL-1ra/IL-1beta (p < 0.00001) constitutively produced by PBMC (ratio < 100) compared with nonresponding (ACR < 20) patients (males 7.7%; ratio > 100). The ratios in 3 female poor responders (ACR 20-50) were in between. The decreased ratios of IL-1ra/IL-1beta in most good and excellent responders were due to an enhanced constitutive IL-1beta release from PBMC (p < 0.004) compared to the groups of non or poor responders. Much less pronounced, there was a slightly significant increase of sTNFR p55 shedding from PBMC and increase of sTNFR p75 serum levels in good and excellent responders (both p < 0.02). In contrast, there were no intergroup differences regarding constitutive IL-1ra release, sTNFR p75 shedding, and IL-1ra and sTNFR p55 serum levels and various demographic and disease associated characteristics of patients. CONCLUSION: Determination of cellularly produced IL-1beta and even more of the IL-1ra/IL-1beta synthesis in PBMC may be useful to predict the outcome of RA patients undergoing treatment with MTX and may characterize a subset of RA that is more responsive to IL-1 directed therapeutic interventions.

PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 30, Issue 1
1 Jan 2003
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate.
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate.
Michael Seitz, Marianne Zwicker, Peter M Villiger
The Journal of Rheumatology Jan 2003, 30 (1) 28-35;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate.
Michael Seitz, Marianne Zwicker, Peter M Villiger
The Journal of Rheumatology Jan 2003, 30 (1) 28-35;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Save to my folders

Jump to section

  • Article
  • References
  • Info & Metrics
  • PDF
  • eLetters

Related Articles

Cited By...

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2016 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire